APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?
APCCC 2024, metastatic hormone-sensitive prostate cancer (mHSPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), ARCHES trial, enzalutamide, Delta-like ligand 3 (DLL3), LuPSMA.